Macrogen Inc (038290) - Net Assets
Based on the latest financial reports, Macrogen Inc (038290) has net assets worth ₩168.36 Billion KRW (≈ $114.09 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩341.60 Billion ≈ $231.50 Million USD) and total liabilities (₩173.25 Billion ≈ $117.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 038290 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩168.36 Billion |
| % of Total Assets | 49.28% |
| Annual Growth Rate | 11.5% |
| 5-Year Change | -10.46% |
| 10-Year Change | 133.11% |
| Growth Volatility | 20.81 |
Macrogen Inc - Net Assets Trend (2011–2024)
This chart illustrates how Macrogen Inc's net assets have evolved over time, based on quarterly financial data. Also explore Macrogen Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Macrogen Inc (2011–2024)
The table below shows the annual net assets of Macrogen Inc from 2011 to 2024. For live valuation and market cap data, see how much is Macrogen Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩177.43 Billion ≈ $120.24 Million |
+11.46% |
| 2023-12-31 | ₩159.19 Billion ≈ $107.88 Million |
-11.23% |
| 2022-12-31 | ₩179.32 Billion ≈ $121.52 Million |
-10.63% |
| 2021-12-31 | ₩200.64 Billion ≈ $135.97 Million |
+1.26% |
| 2020-12-31 | ₩198.15 Billion ≈ $134.28 Million |
+74.84% |
| 2019-12-31 | ₩113.33 Billion ≈ $76.80 Million |
-3.97% |
| 2018-12-31 | ₩118.01 Billion ≈ $79.98 Million |
+25.17% |
| 2017-12-31 | ₩94.28 Billion ≈ $63.89 Million |
+14.21% |
| 2016-12-31 | ₩82.55 Billion ≈ $55.94 Million |
+8.46% |
| 2015-12-31 | ₩76.11 Billion ≈ $51.58 Million |
+13.38% |
| 2014-12-31 | ₩67.13 Billion ≈ $45.49 Million |
+11.80% |
| 2013-12-31 | ₩60.05 Billion ≈ $40.69 Million |
+16.12% |
| 2012-12-31 | ₩51.71 Billion ≈ $35.05 Million |
+19.97% |
| 2011-12-31 | ₩43.11 Billion ≈ $29.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Macrogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6685450379000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩66.85 Billion | 41.57% |
| Common Stock | ₩5.42 Billion | 3.37% |
| Other Components | ₩88.55 Billion | 55.06% |
| Total Equity | ₩160.82 Billion | 100.00% |
Macrogen Inc Competitors by Market Cap
The table below lists competitors of Macrogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
W5 Solutions AB
ST:W5
|
$106.77 Million |
|
TOPMATERIAL LTD
KQ:360070
|
$106.77 Million |
|
Singha Estate Public Company Limited
BK:S
|
$106.81 Million |
|
S&D Co. Ltd.
KQ:260970
|
$106.84 Million |
|
Beta Systems Software AG
F:SPT6
|
$106.76 Million |
|
Sambo Corrugated Board Co. Ltd
KQ:023600
|
$106.75 Million |
|
Pioneer Diversified High IT
NYSE MKT:HNW
|
$106.73 Million |
|
Seah Spe Steel
KO:019440
|
$106.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Macrogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 159,190,685,230 to 160,823,227,140, a change of 1,632,541,910 (1.0%).
- Net loss of 7,603,104,930 reduced equity.
- Dividend payments of 2,991,692,100 reduced retained earnings.
- Share repurchases of 49,739,940 reduced equity.
- Other factors increased equity by 12,277,078,880.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.60 Billion | -4.73% |
| Dividends Paid | ₩2.99 Billion | -1.86% |
| Share Repurchases | ₩49.74 Million | -0.03% |
| Other Changes | ₩12.28 Billion | +7.63% |
| Total Change | ₩- | 1.03% |
Book Value vs Market Value Analysis
This analysis compares Macrogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.69x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9296.03 | ₩15720.00 | x |
| 2017-12-31 | ₩10360.25 | ₩15720.00 | x |
| 2018-12-31 | ₩11778.45 | ₩15720.00 | x |
| 2019-12-31 | ₩11480.44 | ₩15720.00 | x |
| 2020-12-31 | ₩20306.42 | ₩15720.00 | x |
| 2021-12-31 | ₩20289.98 | ₩15720.00 | x |
| 2022-12-31 | ₩17860.79 | ₩15720.00 | x |
| 2023-12-31 | ₩15952.47 | ₩15720.00 | x |
| 2024-12-31 | ₩14834.18 | ₩15720.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Macrogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.60%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 2.05x
- Recent ROE (-4.73%) is below the historical average (5.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 7.35% | 9.69% | 0.56x | 1.35x | ₩-1.13 Billion |
| 2012 | 6.66% | 7.76% | 0.54x | 1.60x | ₩-1.72 Billion |
| 2013 | 10.79% | 13.42% | 0.55x | 1.47x | ₩474.52 Million |
| 2014 | 4.54% | 5.60% | 0.47x | 1.74x | ₩-3.65 Billion |
| 2015 | 13.36% | 12.79% | 0.59x | 1.76x | ₩2.56 Billion |
| 2016 | 5.21% | 4.72% | 0.57x | 1.93x | ₩-3.95 Billion |
| 2017 | 10.11% | 9.36% | 0.57x | 1.90x | ₩101.06 Million |
| 2018 | 2.24% | 2.34% | 0.63x | 1.52x | ₩-9.16 Billion |
| 2019 | -3.09% | -2.86% | 0.54x | 1.99x | ₩-14.83 Billion |
| 2020 | 44.58% | 78.45% | 0.39x | 1.45x | ₩68.52 Billion |
| 2021 | 0.55% | 0.86% | 0.43x | 1.50x | ₩-18.95 Billion |
| 2022 | -12.41% | -16.05% | 0.49x | 1.56x | ₩-40.18 Billion |
| 2023 | -10.56% | -12.66% | 0.52x | 1.62x | ₩-32.73 Billion |
| 2024 | -4.73% | -5.60% | 0.41x | 2.05x | ₩-23.69 Billion |
Industry Comparison
This section compares Macrogen Inc's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $94,149,397,755
- Average return on equity (ROE) among peers: -8.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Macrogen Inc (038290) | ₩168.36 Billion | 7.35% | 1.03x | $106.76 Million |
| Panagene Inc (046210) | $17.92 Billion | -74.89% | 0.84x | $44.65 Million |
| Cell Biotech Co. Ltd (049960) | $108.09 Billion | 7.66% | 0.07x | $82.14 Million |
| Bioneer Corporation (064550) | $203.05 Billion | 13.38% | 0.29x | $150.20 Million |
| MEDIPOST Co. Ltd (078160) | $159.48 Billion | -0.43% | 0.59x | $277.76 Million |
| Biotoxtech Co. Ltd (086040) | $31.25 Billion | 11.60% | 1.02x | $31.03 Million |
| Peptron Inc (087010) | $45.10 Billion | -8.26% | 0.59x | $2.80 Billion |
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more